In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Adial Pharmaceuticals (ADIL – Research Report), with a price target of $5.00. The company’s shares closed last Tuesday at $1.21, close to its 52-week low of $1.13.
According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -41.3% and a 10.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group.
Currently, the analyst consensus on Adial Pharmaceuticals is a Moderate Buy with an average price target of $8.50, a 569.3% upside from current levels. In a report issued on June 15, Brookline Capital Markets also reiterated a Buy rating on the stock with a price target.
The company has a one-year high of $5.08 and a one-year low of $1.13. Currently, Adial Pharmaceuticals has an average volume of 180.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which is focused on the treatment of alcohol use disorder. Its lead product AD04, a selective serotonin-3 antagonist is in Phase 3 clinical trial. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.
Read More on ADIL:
- Goldman Sachs Sees Doom and Gloom in Coinbase Stock, Remains Cautious on Robinhood
- Holding(s) in Shares
- Life Cycle Analysis Confirms Environmental Superiority of CoalSwitch® Reduces CO2 Emissions by 99% Relative to Coal and 97% Relative to Natural Gas
- Synaptics’ Founder Carver Mead Honored with 2022 Kyoto Prize — Japan’s Highest Private Award for Global Achievement
- Nike (NKE) Received its Third Buy in a Row